Techulon Revenue and Competitors
Estimated Revenue & Valuation
- Techulon's estimated annual revenue is currently $310k per year.
- Techulon's estimated revenue per employee is $155,000
Employee Data
- Techulon has 2 Employees.
- Techulon grew their employee count by 0% last year.
Techulon's People
Name | Title | Email/Phone |
---|
Techulon Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.4M | 9 | -10% | N/A | N/A |
#2 | $4.3M | 28 | 4% | N/A | N/A |
#3 | $1.1M | 7 | 0% | N/A | N/A |
#4 | $3.5M | 45 | -52% | $56.5M | N/A |
#5 | $0.3M | 2 | 0% | N/A | N/A |
#6 | $4.5M | 29 | 21% | N/A | N/A |
#7 | $1.9M | 12 | 9% | N/A | N/A |
#8 | $7M | 45 | 5% | N/A | N/A |
#9 | $6.7M | 43 | 5% | N/A | N/A |
#10 | $2M | 13 | -13% | N/A | N/A |
What Is Techulon?
Techulon is leading the next generation of disease treatment through development of safe and effective treatments for drug resistant infections. The company uses a proven method to defeat bacteria at the genomic level. Unlike current antibiotics on the market, the drugs that are derived from Techulon’s approach are potent and not susceptible to resistance.Techulon's enabling technology is a robust platform that allows for delivery of nucleic acids for a variety of therapeutic applications. The company has recently been awarded a $1.9M contract from DARPA to advance its antimicrobial platform to fight both Gram-negative as well as Gram-positive bacteria. Using a novel informatics approach, the company has identified new gene targets and is developing antimicrobial therapeutics for broad applications.
keywords:N/AN/A
Total Funding
2
Number of Employees
$310k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.2M | 2 | 0% | N/A |
#2 | N/A | 2 | -33% | N/A |
#3 | $0.4M | 3 | -40% | N/A |
#4 | $0.3M | 4 | -33% | N/A |
#5 | $0.6M | 4 | -33% | N/A |